These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25648635)

  • 1. DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.
    Zhang L; Zhang Q; Li L; Wang Z; Ying J; Fan Y; He Q; Lv T; Han W; Li J; Yang Y; Xu B; Wang L; Liu Q; Sun Y; Guo Y; Tao Q; Jin J
    J Mol Med (Berl); 2015 Jun; 93(6):691-701. PubMed ID: 25648635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas.
    Li L; Xu J; Qiu G; Ying J; Du Z; Xiang T; Wong KY; Srivastava G; Zhu XF; Mok TS; Chan AT; Chan FK; Ambinder RF; Tao Q
    Theranostics; 2018; 8(1):61-77. PubMed ID: 29290793
    [No Abstract]   [Full Text] [Related]  

  • 3. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.
    Kwong J; Lee JY; Wong KK; Zhou X; Wong DT; Lo KW; Welch WR; Berkowitz RS; Mok SC
    Neoplasia; 2006 Apr; 8(4):268-78. PubMed ID: 16756719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers.
    Ying J; Poon FF; Yu J; Geng H; Wong AH; Qiu GH; Goh HK; Rha SY; Tian L; Chan AT; Sung JJ; Tao Q
    Br J Cancer; 2009 Feb; 100(4):663-9. PubMed ID: 19156137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.
    Wang Z; Li L; Su X; Gao Z; Srivastava G; Murray PG; Ambinder R; Tao Q
    J Transl Med; 2012 Oct; 10():209. PubMed ID: 23050586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1.
    Guo Y; Shu L; Zhang C; Su ZY; Kong AN
    Biochem Pharmacol; 2015 Mar; 94(2):69-78. PubMed ID: 25640947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage.
    Zhang Q; Ying J; Li J; Fan Y; Poon FF; Ng KM; Tao Q; Jin J
    J Urol; 2010 Aug; 184(2):731-7. PubMed ID: 20639048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
    Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
    Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma.
    Seven D; Yavuz E; Kilic E; Baltaci E; Karaman E; Ulutin T; Buyru N
    Gene; 2015 May; 563(1):83-6. PubMed ID: 25746324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma.
    Kwong J; Chow LS; Wong AY; Hung WK; Chung GT; To KF; Chan FL; Daigo Y; Nakamura Y; Huang DP; Lo KW
    Genes Chromosomes Cancer; 2007 Feb; 46(2):171-80. PubMed ID: 17099870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional repression of DLEC1 associates with the depth of tumor invasion in oral squamous cell carcinoma.
    Chan WH; Chang KP; Yang SW; Yao TC; Ko TY; Lee YS; Tsai CL; Tsai CN
    Oral Oncol; 2010 Dec; 46(12):874-9. PubMed ID: 20952247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.
    Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP
    Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
    Kumar SR; Bryan JN; Esebua M; Amos-Landgraf J; May TJ
    BMC Cancer; 2017 Feb; 17(1):158. PubMed ID: 28235398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene.
    Zhang J; Liu L; Pfeifer GP
    Oncogene; 2004 Mar; 23(12):2241-9. PubMed ID: 14691453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle.
    Qiu GH; Salto-Tellez M; Ross JA; Yeo W; Cui Y; Wheelhouse N; Chen GG; Harrison D; Lai P; Tao Q; Hooi SC
    J Hepatol; 2008 Mar; 48(3):433-41. PubMed ID: 18191269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
    Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
    Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma.
    Seng TJ; Currey N; Cooper WA; Lee CS; Chan C; Horvath L; Sutherland RL; Kennedy C; McCaughan B; Kohonen-Corish MR
    Br J Cancer; 2008 Jul; 99(2):375-82. PubMed ID: 18594535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.